Upon reviewing repeated prostate cancer screenings, researchers observed the absence of suspicious MRI findings in over 86% of men who had prostate-specific antigen (PSA) levels of 3 ng/mL or higher ...

High-resolution microultrasonography-guided biopsy was non-inferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer (detection rates, 47.1% and 42.6%, respectively), a ...

What these buzzy new tests can and can't tell you.

In a randomized trial of men with a single suspicious lesion on MRI, targeted perilesional biopsy matched standard targeted and systematic biopsy for detecting clinically significant prostate cancer - ...

Can PSA derivatives reduce unnecessary prostate MRI after negative biopsy? Learn how simple markers may guide imaging ...

Microultrasonography for prostate biopsy detected clinically significant cancer at rates comparable to MRI-guided approaches. Detection rates for clinically insignificant cancers did not differ among ...

A combined PSMA-PET/MRI scanner better detected clinically significant prostate cancer in men on active surveillance. The addition of piflufolastat F18 (18 F-DCFPyL) prostate-specific membrane antigen ...

Targeting men in the top 10% of genetic risk helped detect high-grade prostate cancer that conventional screening would miss, paving the way for more personalized and effective early detection ...

Advanced imaging, particularly PSMA PET scans, enhances detection of microscopic disease, allowing for more precise treatment ...

Koelis, SAS ("Koelis" or the "Company", a leader and innovator in MRI-ultrasound fusion guidance for prostate cancer interventions, recently announced that the Centers for Medicare & Medicaid ...